🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re excited to announce that our treatment for paroxysmal nocturnal hemoglobinuria (PNH) has been approved in the EU! Learn more: investors.apellis.com/news-releases/…

With over 20 years of experience studying complement, our world-class researchers are advancing courageous science with the goal of slowing progression of #GeographicAtrophy. #LeadersInComplement

Take a journey into the retina and check out how complement overactivation may accelerate damage and increase lesion growth in #GeographicAtrophy (GA): bit.ly/3oU7tn6 #Apellis #LeadersInComplement

Compstatins: the dawn of clinical C3-targeted complement inhibition, online now, review article from Christina Lamers, Dimitrios C. Mastellos, Daniel Ricklin and John D. Lambris. Christina Lamers Dimitris Mastellos John D. Lambris, Ph.D. NCSR Demokritos Penn Path & Lab Medicine cell.com/trends/pharmac…

Paroxysmal Nocturnal Hemoglobinuria is a rare blood disease. There are now 3 approved complement inhibitors for PNH: 💊Eculizumab 💊Ravulizumab 💊Pegcetacoplan Making it a success story for #complementbiology! Great to follow the progress in this area: bit.ly/3J4ciBp

Great work in Elsevier Immunology on the importance of #complementbiology in IgA-vasculitis by my former colleague Dr. Damman at the Erasmus MC: - bit.ly/3LjZHff Similar to IgA Nephropathy, there is cutaneous activation of the lectin & alternative pathway in IgA-vasculitis!

When the complement cascade is overactivated, it can attack and destroy healthy cells, leading to serious diseases. Our focus at Apellis is to control complement at C3. Learn more about the complement cascade and our work. #LeadersInComplement #WeAreApellis

For those living with #GeographicAtrophy (GA), like Santi, the impact is real. Learn more about Apellis and the GA disease state.

We’re excited to announce that seven abstracts will be presented at the European Hematology Association Annual Meeting showcasing our leadership in paroxysmal nocturnal hemoglobinuria (#PNH). Read more.

We are proud to celebrate the one-year mark of the FDA approval of our paroxysmal nocturnal hemoglobinuria (#PNH) treatment – a significant milestone for people living with this rare blood disorder. #LeadersInComplement

Delighted to share the first article of a #specialssue in #Seminars in #Immunology focused on recent developments in #C3-targeted #complementTherapeutics! Stay tuned for a fascinating collection capturing the drastic transformation of this evolving field! sciencedirect.com/science/articl…

Our ability to diagnose & treat diseases caused by complement dysregulation has advanced greatly in the past 20 years. This Review offers an overview of these developments, focusing on single-gene, complement-driven aHUS & C3-dominant glomerulopathies bit.ly/CJN11830720

Successful #aHUS treatment tapering based on complement classical pathway activity not alternative pathway a new insight #Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and dru… pubmed.ncbi.nlm.nih.gov/35013983/

Today, we announced that we submitted a new drug application to the FDA for our investigational therapy for the treatment of #geographicatrophy (GA), a leading cause of blindness. Read more: investors.apellis.com/news-releases/…

The first patient has been dosed in our Phase 3 IC-MPGN and C3G study! This milestone is a testament to our continued pursuit to help patients living with these rare kidney diseases. Learn more. #Apellis #LeadersInComplement #CourageousScience investors.apellis.com/news-releases/…

Yesterday, we were proud to have #Apellis co-founder and CEO cedric francois share his expertise on a panel at #BIO2022. He discussed #TeamApellis’ drive for innovation and pursuit of groundbreaking science, even in a challenging market. #LeadersInComplement

We are excited to announce that the FDA has accepted our new drug application (NDA) for our investigational therapy for #GeographicAtrophy (GA)! Read more about this important milestone. #LeadersInComplement

New paper about inhibition of #complementbiology in a 🐁 model #lupus #nephritis: - bit.ly/3voXUPI 🔑 findings: - a Factor B inhibitor could suppress activation of the alternative pathway in MRL/lpr mice improve the symptoms & signs of lupus nephritis.

Another review on the potential of targeting #complementbiology in #kidney #transplantation: link.springer.com/article/10.100… However, it's a shame that the authors underexposed the opportunity of complement inhibition in the organ donor prior to transplantation: pubmed.ncbi.nlm.nih.gov/27989433/

The NRCTC team will be hosting a roadshow on Saturday 13th May 2023 in York. We are excited to see you all there!